Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferric derisomaltose for preoperative anemia in gynecologic oncology
NCT05467319Phase 3Unknown
- Sponsor
- Alberta Health Services
- Start
- Sep 2022
- Primary completion
- Sep 2023
- Modality
- Inorganic Nanoparticles, Small Molecules
01
Overview
A Phase 3 trial of ferric derisomaltose in iron deficiency anemia (IDA), sponsored by Alberta Health Services. Status: unknown.
02
Drugs
ferric derisomaltose
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NCT05467319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05467319.